ArticleInternational urology and nephrology2025
Efficacy and prognostic analysis of the oXiris® filter in sepsis-associated acute kidney injury.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adjunctive multimodal extracorporeal support in severe septic shock with multi-organ failure: a case report.Frontiers in medicine · 2026Article
- Association of oXirisJournal of personalized medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to assess the efficacy of the oXiris® filter in CRRT for SA-AKI and its effects on short- and medium-term mortality.
methodsA retrospective cohort study was conducted at the Blood Purification Center of the First Affiliated Hospital of Zhengzhou University from November 2019 to November 2024. Patients with SA-AKI undergoing CRRT were divided into two groups: the M150 group (n = 135) and the oXiris group (n = 126). Laboratory indices, clinical characteristics, and mortality rates at 7, 14, 30, 60, and 90 days were compared between groups to assess the impact of the oXiris filter.
resultsFollowing CRRT, the oXiris group showed a significant increase in MAP (76.24 ± 13.21 vs. 82.34 ± 14.38 mmHg, p < 0.001), with a decrease in SI (0.96 [0.75, 1.15] vs. 0.80 [0.64, 1.00], p < 0.001), Lac (3.00 [1.70, 6.55] vs. 2.00 [1.40, 3.10] mmol/L, p < 0.001), and IL-6 (174.40 [51.21, 1474.44] vs. 127.20 [35.29, 655.30] pg/ml, p = 0.045) compared to baseline, whereas no such changes were observed in the M150 group. Additionally, the total norepinephrine dose was lower in the oXiris group (108.00[16.00,295.50] vs. 194.00[18.00,500.00] mg, p = 0.020). No significant differences in 7-day, 14-day, 30-day, 60-day, or 90-day mortality were observed between the groups after CRRT initiation.
conclusionThe oXiris filter improves short-term hemodynamics, inflammation, and microcirculatory dysfunction in SA-AKI, but does not reduce short- or medium-term mortality compared to the M150 group.
Indexed as
Identifiers
40274725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.